Preventable deaths, preventable delays: structural heart disease care needs to be a priority in its own right
Every year, patients in England die from structural heart diseases when earlier intervention could have saved them. Treatments exist and are effective, and outcomes when patients are treated in time are good, yet the system is failing to reach people before it is too late. This is not acceptable, and ...
Data rich, intelligence poor: what to do about it before January
“We are data-rich, but I think it’s fair to say we’re intelligence-poor.”
From hospitals to homes – unlocking the potential of clinical homecare
As the NHS rethinks where specialist care should happen, established clinical homecare services could play a greater role in transforming patient pathways and supporting NHS capacity.
Case study: Easing winter bed pressure through strategic homecare choices
24 November, 2026 | 10:30 am - 11:15 am
Modernising diagnostic imaging: a flexible approach to long-term investment
How a vendor-neutral managed equipment service is helping Oxford University Hospitals Foundation Trust plan for the future of diagnostic imaging
The doctor will see you… online? Caroline Clarke on building a new NHS trust
Thirty-five years ago, Caroline Clarke began her NHS journey, and today she is the founding CEO of NHS Online.
How treating inflammatory bowel disease (IBD) can help shape the future of NHS care
Having had the privilege to work within both the NHS and the UK pharmaceutical industry, I have seen how scientific progress can achieve its greatest impact when it is supported by an integrated healthcare system.
Time to Breathe: Too many people are dying from ILD – commissioners can help change that
This article summarises findings from the Time to Breathe roundtable, a Boehringer Ingelheim-funded and commissioned initiative involving respiratory clinicians, commissioners, service leads and patient organisation representatives. Participants were compensated for their time. The article has been developed independently by Boehringer Ingelheim and reflects the discussions and recommendations arising from that ...
Understanding the deprescribing landscape: what our survey of NHS pharmacy stakeholders tells us
Aspire Pharma Ltd initiated and funded this article but had no input into the content and was able to review it in advance of publication for factual accuracy and compliance checks only.